Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict...

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Staphylococcus aureus is a significant pathogen causing serious infections.
• Antibiotic resistance in S. aureus is a growing concern.
• Vancomycin and teicoplanin are key glycopeptide antibiotics used to treat S. aureus infections.

Purpose of the Study:

• To evaluate the in vivo efficacy of vancomycin and teicoplanin.
• To compare their effectiveness against Staphylococcus aureus strains with varying susceptibilities.
• To determine if in vitro susceptibility predicts in vivo outcomes.

Main Methods:

• Endocarditis was induced in rabbits using five different S. aureus strains.
• Animals were treated for 2 days with either vancomycin or teicoplanin.
• Treatment groups were compared to untreated control groups infected with the same strains.

Main Results:

• Vancomycin and teicoplanin exhibited similar in vivo efficacy against the tested S. aureus strains.
• The in vitro minimum inhibitory concentrations (MICs) did not correlate with in vivo treatment effectiveness.
• Both antibiotics showed comparable activity regardless of methicillin susceptibility.

Conclusions:

• Vancomycin and teicoplanin are similarly effective in treating S. aureus endocarditis in a rabbit model.
• In vitro susceptibility testing (MICs) may not be a sufficient predictor of in vivo treatment response for these antibiotics.
• Further research is needed to understand factors influencing glycopeptide efficacy in vivo.